Current version snapshot

FDA-approved↗↗↗↗↗Endocrine↗

Current · version 4: Octreotide↗

Related names recorded in this version: Octreotide acetate, Sandostatin↗↗

A somatostatin analogue first approved by FDA as Sandostatin in 1988, used for acromegaly and for diarrhea and flushing caused by certain hormone-secreting tumors.↗↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 16, 2026

We added the FDA labels of Sandostatin LAR and Mycapssa and now describe each trial with the octreotide product it tested, because the generic label cited on this page has no clinical studies section. 89

What this version reported

The generic label cited here describes no trials of its own and states that its trials did not show improvement in symptoms or tumor size. Randomized trials of two other octreotide products, Sandostatin LAR and Mycapssa, are described in their own FDA labels.↗↗↗↗↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗
  • U.S. Food and Drug Administration↗

Reader guide in this version

Key takeaway

Octreotide is a lab-made peptide that mimics somatostatin, a hormone that suppresses growth hormone and several gut hormones. It was first approved in the United States as Sandostatin in 1988.1,2 It is FDA-approved to lower growth hormone and IGF-1 in acromegaly when other treatments have not worked or cannot be used, and to treat severe diarrhea and flushing from metastatic carcinoid tumors and watery diarrhea from VIP-secreting tumors.1 Its controlled trials are described product by product: the labels of Sandostatin LAR and Mycapssa each report randomized trials of that product, while the generic label cited here describes none and states that its trials did not show improvement in symptoms or tumor size.1,8,9

At a glance

What it is
A somatostatin analogue. The label states that it acts like natural somatostatin and is an even more potent inhibitor of growth hormone, glucagon and insulin.1
FDA status
FDA-approved. Drugs@FDA lists Sandostatin with an original approval date of October 21, 1988, and later octreotide products including Sandostatin LAR, Mycapssa and Bynfezia. The cited label has no boxed warning.1,2,3,4,5
Human evidence
Smaller randomized trials, each of a named octreotide product: a carcinoid syndrome trial in 93 people in the Sandostatin LAR label, a placebo-controlled acromegaly trial in 56 people in the Mycapssa label, and two published acromegaly trials.6,7,8,9
Evidence strength
Smaller controlled human trials

What is octreotide?

Octreotide is a lab-made peptide that the label says exerts actions similar to the natural hormone somatostatin.1

Drugs@FDA lists it as the active ingredient of Sandostatin (1988), Sandostatin LAR (1998), Mycapssa (2020) and Bynfezia (2024), among other octreotide applications. The label cited on this page is a generic octreotide label; Sandostatin LAR and Mycapssa have labels of their own.1,2,3,4,5,8,9

How does octreotide work?

The label states that octreotide is an even more potent inhibitor of growth hormone, glucagon and insulin than somatostatin, and that it also reduces blood flow to the gut organs and the release of serotonin and several gut hormones.1

The label states that it substantially reduces growth hormone and IGF-1 levels in people with acromegaly.1

What do human studies show?

The generic label cited on this page has no clinical studies section. The trials below are each named with the octreotide product they tested.1

Sandostatin LAR: in a six-month trial in 93 people with malignant carcinoid syndrome, diarrhea and flushing were about as well controlled on Sandostatin LAR as on Sandostatin, although about half to two-thirds of those who completed the trial on Sandostatin LAR also needed short-acting Sandostatin at times to control flare-ups, according to its label.8

Sandostatin LAR: in three trials of people with acromegaly already controlled on Sandostatin, growth hormone, IGF-1 and symptoms were at least as well controlled after switching to Sandostatin LAR; these trials had no placebo group. In two open-label studies in 143 untreated people, median tumor volume fell by about 21% to 25% at 24 weeks, according to its label.8

Mycapssa: in a nine-month randomized, placebo-controlled trial in 56 people with acromegaly, 58% on Mycapssa kept IGF-1 within the normal range compared with 19% on placebo, and 25% switched back to other somatostatin analogues, according to its label.9

In MPOWERED, 92 adults with acromegaly who had already responded to treatment were randomized to Mycapssa or to their previous somatostatin-analogue treatment. Biochemical response was maintained in 91% and 100% respectively, which met the trial’s prespecified non-inferiority criterion.7

A 1990 double-blind, randomized trial assigned 20 people with acromegaly to octreotide or placebo for 14 days. Average growth hormone and IGF-1 levels fell significantly with octreotide, although two treated participants had no significant fall in growth hormone.6

What the evidence base contains

  • Controlled human trial Sandostatin LAR: a six-month trial in 93 people with malignant carcinoid syndrome who had responded to Sandostatin, 67 randomized to three blinded strengths of Sandostatin LAR and 26 continuing unblinded on Sandostatin, described in the Sandostatin LAR label.8
  • Controlled human trial Mycapssa: a nine-month randomized, double-blind, placebo-controlled trial in 56 people with acromegaly, described in the Mycapssa label as the trial that established its efficacy.9
  • Controlled human trial A double-blind, randomized, placebo-controlled trial of octreotide in 20 people with acromegaly, published in 1990, that measured growth hormone and IGF-1 over 14 days.6
  • Controlled human trial MPOWERED: an open-label, randomized Phase 3 trial in 92 adults with acromegaly who had already responded to treatment, comparing Mycapssa with the somatostatin-analogue treatment they had been receiving.7
  • Small, short, or incompletely reported human study Sandostatin LAR: three trials in people with acromegaly already controlled on Sandostatin who switched to Sandostatin LAR (101 people in two trials and 151 in a third), and two open-label studies in 143 untreated people, described in the Sandostatin LAR label.8

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is octreotide FDA-approved?

Yes. Drugs@FDA lists Sandostatin, application NDA019667, with an original approval date of October 21, 1988, Sandostatin LAR on November 25, 1998, Mycapssa on June 26, 2020 and Bynfezia on September 27, 2024.2,3,4,5

The generic octreotide label cited here (DailyMed SPL version 2, published February 2, 2026) states that it is indicated to reduce growth hormone and IGF-1 in acromegaly when surgery, pituitary radiation and bromocriptine have not worked or cannot be used, to treat severe diarrhea and flushing from metastatic carcinoid tumors, and to treat watery diarrhea from VIP-secreting tumors.1

The label states that trials of this product did not show improvement in clinical signs and symptoms or a reduction in tumor size or growth rate, and that the trials were not designed to detect these effects.1

The label has no boxed warning. It states that octreotide is contraindicated in people sensitive to it, and its warnings cover heart rhythm and conduction problems, gallstones and their complications, high or low blood sugar, thyroid function changes, poor fat absorption and changes in vitamin B12 levels.1

The Mycapssa label, revised July 2024, states that Mycapssa is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated octreotide or lanreotide.9

Timeline

  1. FDA approves Sandostatin, according to Drugs@FDA.2
  2. Results of a placebo-controlled acromegaly trial of octreotide are published.6
  3. FDA approves Sandostatin LAR, according to Drugs@FDA.3
  4. FDA approves Mycapssa, according to Drugs@FDA.4
  5. The Sandostatin LAR and Mycapssa labels cited on this page are revised in July 2024.8,9
  6. FDA approves Bynfezia, according to Drugs@FDA.5
  7. DailyMed publishes the octreotide label version cited on this page.1

What is still unknown?

Whether the product on the generic label improves symptoms or slows tumor growth, which the label says its trials were not designed to detect.1

How far results for one octreotide product carry over to another: the controlled trials reviewed here tested Sandostatin LAR or Mycapssa, and the generic label describes no trials of its own.1,7,8,9

Sources for this version

  1. 1
    Octreotide acetate injection, solution · SPL version 2 · published 2026-02-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA019667 · original submission status AP · 1988-10-21 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA021008 · original submission status AP · 1998-11-25 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA208232 · original submission status AP · 2020-06-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA213224 · original submission status AP · 2024-09-27 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects (1990) · PMID 2229278 ↗

    The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 14, 2026

  7. 7
    Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial (MPOWERED, 2022) · PMID 34953531 ↗

    The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026

  8. 8
    Sandostatin LAR Depot (octreotide acetate) prescribing information, NDA 021008 supplement S-049, revised July 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  9. 9
    Mycapssa (octreotide) prescribing information, NDA 208232 supplement S-006, revised July 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026